Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation and Depletion (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Depreciation and Depletion for 9 consecutive years, with $321000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 4.18% to $321000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 13.2% year-over-year, with the annual reading at $1.3 million for FY2025, 13.2% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $321000.0 at Akebia Therapeutics, up from $318000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $408000.0 in Q4 2022, with the low at $314000.0 in Q1 2025.
  • Average Depreciation and Depletion over 4 years is $363384.6, with a median of $364000.0 recorded in 2024.
  • The sharpest move saw Depreciation and Depletion grew 0.76% in 2024, then dropped 21.0% in 2025.
  • Over 4 years, Depreciation and Depletion stood at $408000.0 in 2022, then fell by 3.43% to $394000.0 in 2023, then decreased by 14.97% to $335000.0 in 2024, then fell by 4.18% to $321000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $321000.0, $318000.0, and $316000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.